Of these randomised patients , 156 were treated in the combination phase ( 81 in the olaparib plus chemotherapy group and 75 in the chemotherapy alone group ) and 121 continued to the maintenance or no further treatment phase ( 66 in the olaparib plus chemotherapy group and 55 in the chemotherapy alone group ) .